|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
girls and women aged 9 to 25 years
|
|
gptkbp:alternativeTo
|
gptkb:Gardasil
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:J07BM02
|
|
gptkbp:broadcastOn
|
2 or 3 dose series
|
|
gptkbp:category
|
HPV vaccine
|
|
gptkbp:composition
|
gptkb:HPV-16_L1_protein
gptkb:HPV-18_L1_protein
gptkb:monophosphoryl_lipid_A
aluminum hydroxide
|
|
gptkbp:contains
|
gptkb:AS04_adjuvant
virus-like particles
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cervarix
|
|
gptkbp:indication
|
prevention of cervical cancer
prevention of precancerous lesions
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:marketedIn
|
over 100 countries
|
|
gptkbp:not_indicated_for
|
treatment of cervical cancer
treatment of existing HPV infection
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
|
|
gptkbp:protectionDuration
|
at least 9.4 years (studied)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site pain
myalgia
gastrointestinal symptoms
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:human_papillomavirus
|
|
gptkbp:target_subtype
|
gptkb:HPV_type_16
gptkb:HPV_type_18
|
|
gptkbp:type
|
recombinant vaccine
|
|
gptkbp:WHOPrequalified
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Human_papillomavirus
gptkb:Gardasil
|
|
gptkbp:bfsLayer
|
5
|